<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03946761</url>
  </required_header>
  <id_info>
    <org_study_id>201904180</org_study_id>
    <nct_id>NCT03946761</nct_id>
  </id_info>
  <brief_title>Fluorescence Imaging in Hepatobiliary Surgery</brief_title>
  <official_title>Evaluation of Fluorescence Imaging in Hepatobiliary Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A current gap in the use indocyanine green fluorescence to isolate the biliary system is the
      dosing amount necessary to fluoresce the biliary system without &quot;over&quot; fluorescing the liver
      and gallbladder. Over fluorescing surrounding structures such as the liver and gallbladder
      saturates the image and makes it impossible to identify biliary leaks or differentiate
      branches of the common bile duct using fluorescent imaging devices. The over dosing does not
      affect the standard of care procedure, but eliminates the added benefit of the fluorescent
      imaging technology. The use of &quot;microdoses&quot; (approximately 0.1 mg) of indocyanine green has
      been trialed and shown promise in some patients. This study aims to do an in depth study
      utilizing the Cancer goggle systems fluorescent imaging system to determine the correct dose
      needed to isolate the biliary system without over fluorescing surrounding structures. This
      dosing study could additionally serve as a pilot study for follow on research using
      indocyanine green and fluorescent imaging in hepatobiliary surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The minimum dose of the ICG that causes initial fluorescence of the liver</measure>
    <time_frame>Through completion of surgery for all participants enrolled (estimated to take 1 year)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The visible status of the bile ducts and/or bile leaks from the cut surface of the liver at ICG doses administered in our dosing regimen</measure>
    <time_frame>Through completion of surgery for all participants enrolled (estimated to take 1 year)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatobiliary Surgery</condition>
  <arm_group>
    <arm_group_label>Cancer goggle system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The surgical procedure will be performed according to standard practice, with the exception of microdosing of ICG &amp; visualization of biliary/liver anatomy using the cancer goggles system
The surgeon will start with a peripherally injected microdose of 0.02 mg of ICG &amp; will inject an additional 0.02mg every 5 minutes until a noticeable fluorescent change in the liver is observed. If a change is not observed after 0.14 mg has been injected then the microdosing regimen will stop. Output video from the cancer goggles will be recorded and saved for post-surgical analysis.
Following resection of the liver parenchyma, the portal area and the cut surface of the liver will be analyzed for the identification of bile ducts leaks with or without cancer goggles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cancer goggle system</intervention_name>
    <description>-The cancer goggle system is being used as a non-significant risk device</description>
    <arm_group_label>Cancer goggle system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned open liver resection or ablation.

          -  At least 18 years of age.

          -  Able to understand and willing to sign a written informed consent document.

        Exclusion Criteria:

        -History of allergic reactions attributed to ICG, iodine, iodine dye, or other agents used
        in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chet Hammill, M.D., FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chet Hammill, M.D., FACS</last_name>
    <phone>314-273-1809</phone>
    <email>hammillc@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Chet Hammill, M.D., FACS</last_name>
      <phone>314-273-1809</phone>
      <email>hammillc@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Chet Hammill, M.D., FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel Achilefu, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryan Fields, M.D., FACS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Hawkins, M.D., FACS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominic Sanford, M.D., MPHS, FACS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Strasberg, M.D., FACS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adeel Khan, M.D., MPH, FACS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Majella Doyle, M.D., MBA, FACS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Chapman, M.D., FACS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esther Lu, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

